BRIEF-Cocrystal Pharma Receives Irb Approval From Emory University School Of Medicine

Reuters12-18 21:30

BRIEF-<a href="https://laohu8.com/S/COCP">Cocrystal Pharma</a> Receives Irb Approval From Emory University School Of Medicine

Dec 18 (Reuters) - Cocrystal Pharma Inc COCP.O:

COCRYSTAL PHARMA RECEIVES IRB APPROVAL FROM EMORY UNIVERSITY SCHOOL OF MEDICINE FOR PHASE 1B HUMAN CHALLENGE STUDY WITH CDI-988 FOR PREVENTION AND TREATMENT OF NOROVIRUS
COCRYSTAL PHARMA INC - SUBJECT ENROLLMENT FOR STUDY EXPECTED TO BEGIN IN Q1 2026

Source text: ID:nGNXkBgFB

Further company coverage: COCP.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592544909?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592544909","market":"fut","top_or_hot":-1,"title":"BRIEF-Cocrystal Pharma Receives Irb Approval From Emory University School Of Medicine","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/COCP\">Cocrystal Pharma</a> Receives Irb Approval From Emory University School Of Medicine </title></head><body><p><span>Dec 18 (Reuters)</span><span> - </span>Cocrystal Pharma Inc <span>COCP.O</span>:</p><ul><li><p>COCRYSTAL PHARMA RECEIVES IRB APPROVAL FROM EMORY UNIVERSITY SCHOOL OF MEDICINE FOR PHASE 1B HUMAN CHALLENGE STUDY WITH CDI-988 FOR PREVENTION AND TREATMENT OF NOROVIRUS</p></li><li><p>COCRYSTAL PHARMA INC - SUBJECT ENROLLMENT FOR STUDY EXPECTED TO BEGIN IN Q1 2026</p></li></ul><p>Source text: <span>ID:nGNXkBgFB</span></p><p>Further company coverage: <span>COCP.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cocrystal Pharma Receives Irb Approval From Emory University School Of Medicine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cocrystal Pharma Receives Irb Approval From Emory University School Of Medicine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/COCP\">Cocrystal Pharma</a> Receives Irb Approval From Emory University School Of Medicine </title></head><body><p><span>Dec 18 (Reuters)</span><span> - </span>Cocrystal Pharma Inc <span>COCP.O</span>:</p><ul><li><p>COCRYSTAL PHARMA RECEIVES IRB APPROVAL FROM EMORY UNIVERSITY SCHOOL OF MEDICINE FOR PHASE 1B HUMAN CHALLENGE STUDY WITH CDI-988 FOR PREVENTION AND TREATMENT OF NOROVIRUS</p></li><li><p>COCRYSTAL PHARMA INC - SUBJECT ENROLLMENT FOR STUDY EXPECTED TO BEGIN IN Q1 2026</p></li></ul><p>Source text: <span>ID:nGNXkBgFB</span></p><p>Further company coverage: <span>COCP.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUAB8JXV4:1","article_id":"2592544909","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592544909","pubTimestamp":1766064605,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Cocrystal Pharma Receives Irb Approval From Emory University School Of Medicine Dec 18 (Reuters) - Cocrystal Pharma Inc COCP.O:COCRYSTAL PHARMA RECEIVES IRB APPROVAL FROM EMORY UNIVERSITY SCHOOL","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","COCP":"Cocrystal Pharma, Inc."},"translate_title":"简介-Cocrystal Pharma获得埃默里大学医学院Irb批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COCP":0.9},"content_text":"BRIEF-Cocrystal Pharma Receives Irb Approval From Emory University School Of Medicine Dec 18 (Reuters) - Cocrystal Pharma Inc COCP.O:COCRYSTAL PHARMA RECEIVES IRB APPROVAL FROM EMORY UNIVERSITY SCHOOL OF MEDICINE FOR PHASE 1B HUMAN CHALLENGE STUDY WITH CDI-988 FOR PREVENTION AND TREATMENT OF NOROVIRUSCOCRYSTAL PHARMA INC - SUBJECT ENROLLMENT FOR STUDY EXPECTED TO BEGIN IN Q1 2026Source text: ID:nGNXkBgFBFurther company coverage: COCP.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592544909","isCrawlerRequest":true}